Fig. 3: Targeting efficiency and cytotoxicity of T-AsiG-CPL in vitro.
From: Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine
Confocal laser scanning microscopy images of T3M4 (a) and BxPC-3 (b) cells after AsiG-Cy5 (red)-loaded nanoparticles treatment at pH 6.5 for 1 h from three independent experiments (AsiG-Cy5: 250 nM). Nuclei were labeled with DAPI (blue), and cell membranes were labeled with Wheat Germ Agglutinin (WGA, green). anti-CD71, CD71 primary antibody. Scale bars, 20 μm. c Flow cytometry analysis of T3M4 cells after incubation with AsiG-Cy5 loaded formulations at pH 6.5 for 1 h (n = 3 independent experiments; AsiG-Cy5: 250 nM). d Mean fluorescence intensity (MFI) values of different formulations (n = 3 independent experiments). a. u., arbitrary units. e Flow cytometry analysis of BxPC-3 cells after incubation with AsiG-Cy5 loaded formulations at pH 6.5 for 1 h (n = 3 independent experiments, AsiG-Cy5: 250 nM). f MFI values of different formulations (n = 3 independent experiments). Cell viability of T3M4 cells (g), BxPC-3 cells (h), and PSC (i) following different treatments (AsiG: 50 nM; TPCA-1: 20 μM for human PDAC cells and 10 μM for PSC) at pH 7.4 or 6.5 for 48 h (n = 5 independent experiments). The data in (d) and (f–i) are displayed as the mean ± SEM. One-way ANOVA (d, f) and two-way ANOVA (g–i) with Bonferroni’s multiple comparisons test were used for statistical significance analysis. Source data are provided as a Source Data file.
